MX361432B - Métodos para diagnóstico del cáncer. - Google Patents

Métodos para diagnóstico del cáncer.

Info

Publication number
MX361432B
MX361432B MX2017001051A MX2017001051A MX361432B MX 361432 B MX361432 B MX 361432B MX 2017001051 A MX2017001051 A MX 2017001051A MX 2017001051 A MX2017001051 A MX 2017001051A MX 361432 B MX361432 B MX 361432B
Authority
MX
Mexico
Prior art keywords
diagnosis
cancer
compositions
treatment
methods
Prior art date
Application number
MX2017001051A
Other languages
English (en)
Inventor
Sahin Ugur
Türeci Özlem
Koslowski Michael
Walter Korden
Wöll Stefan
Helftenbein Gerd
Oprea Gabriela-Elena
Original Assignee
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09002452A external-priority patent/EP2221375A1/en
Application filed by Ganymed Pharmaceuticals Ag filed Critical Ganymed Pharmaceuticals Ag
Publication of MX361432B publication Critical patent/MX361432B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

La presente invención se refiere a la identificación de secuencias de ácido nucleico y aminoácidos que son características de tejidos tumorales tales como tejidos tumorales de ovarios y tumorales de pulmón y que representan objetivos para terapia o diagnóstico de enfermedades tumorales en un sujeto.
MX2017001051A 2009-02-20 2010-02-19 Métodos para diagnóstico del cáncer. MX361432B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15416709P 2009-02-20 2009-02-20
EP09002452A EP2221375A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
US23184309P 2009-08-06 2009-08-06
EP09010164 2009-08-06
US26013509P 2009-11-11 2009-11-11
EP09014135 2009-11-11
PCT/EP2010/001062 WO2010094499A1 (en) 2009-02-20 2010-02-19 Methods and compositions for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
MX361432B true MX361432B (es) 2018-12-05

Family

ID=42114454

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2011008430A MX2011008430A (es) 2009-02-20 2010-02-19 Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2014012968A MX345316B (es) 2009-02-20 2010-02-19 Métodos y composiciones para diagnóstico y tratamiento del cáncer.
MX2017001051A MX361432B (es) 2009-02-20 2010-02-19 Métodos para diagnóstico del cáncer.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2011008430A MX2011008430A (es) 2009-02-20 2010-02-19 Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2014012968A MX345316B (es) 2009-02-20 2010-02-19 Métodos y composiciones para diagnóstico y tratamiento del cáncer.

Country Status (23)

Country Link
US (4) US9809815B2 (es)
EP (2) EP2398902B1 (es)
JP (1) JP5808254B2 (es)
KR (3) KR102152997B1 (es)
CN (2) CN107028969A (es)
AU (2) AU2010215700B2 (es)
BR (1) BRPI1008564B1 (es)
CA (1) CA2750985C (es)
DK (1) DK2398902T3 (es)
ES (1) ES2963717T3 (es)
FI (1) FI2398902T3 (es)
HR (1) HRP20231525T1 (es)
IL (4) IL214256A0 (es)
LT (1) LT2398902T (es)
MX (3) MX2011008430A (es)
NZ (1) NZ594480A (es)
PL (1) PL2398902T3 (es)
PT (1) PT2398902T (es)
RS (1) RS64937B1 (es)
SG (3) SG173444A1 (es)
SI (1) SI2398902T1 (es)
WO (1) WO2010094499A1 (es)
ZA (1) ZA201105471B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
CA2786940C (en) 2010-03-16 2019-09-24 Biontech Ag Tumor vaccination involving a humoral immune response, and proteins therefor including all or a portion of a hepatitis b virus core antigen protein and an epitope of claudin 18.2
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) * 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
US10329353B2 (en) * 2013-03-05 2019-06-25 Board Of Regents, The University Of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN105813650A (zh) 2013-11-06 2016-07-27 施特姆森特克斯股份有限公司 新型抗-密蛋白抗体和使用方法
LT3126381T (lt) * 2014-04-01 2019-05-27 Biontech Cell&Gene Therapies Gmbh Klaudinui-6 specifiniai imunoreceptoriai ir t ląstelių epitopai
CN111164208B (zh) 2017-09-29 2023-08-04 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2002008288A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20020127584A1 (en) 1997-09-18 2002-09-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5932445A (en) 1997-11-07 1999-08-03 Incyte Pharmaceuticals, Inc. Signal peptide-containing proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
JP2003524384A (ja) 1998-11-03 2003-08-19 アドヘレックス テクノロジーズ インコーポレイテッド クラウディン媒介機能を調節するための化合物および方法
AU3124000A (en) 1998-12-17 2000-07-03 Human Genome Sciences, Inc. 47 human secreted proteins
KR100358062B1 (ko) * 1998-12-30 2003-01-24 주식회사 하이닉스반도체 플래쉬메모리셀및그의제조방법
WO2000050588A2 (en) * 1999-02-22 2000-08-31 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
ES2287020T3 (es) 1999-06-02 2007-12-16 Genentech, Inc. Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas.
EP1067182A3 (en) 1999-07-08 2001-11-21 Helix Research Institute Secretory protein or membrane protein
EP1242443A4 (en) 1999-12-23 2005-06-22 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
AU2001236470A1 (en) 2000-01-14 2001-07-24 Corixa Corporation Ovarian tumor-associated sequences
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004506413A (ja) 2000-06-23 2004-03-04 ジェネンテック・インコーポレーテッド 血管形成に関与する疾患の診断と治療のための組成物と方法
JP2004516013A (ja) 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
US20030100713A1 (en) 2000-07-25 2003-05-29 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040033493A1 (en) * 2001-01-31 2004-02-19 Tchernev Velizar T. Proteins and nucleic acids encoding same
AU2002318371B2 (en) * 2001-06-20 2006-06-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2379661A1 (en) 2002-03-28 2003-09-28 Kursad Turksen Paracellular drug delivery system
CA2481507A1 (en) * 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20070207142A1 (en) 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
AU2003295328A1 (en) 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
NZ581541A (en) 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
CA2503043A1 (en) 2002-10-18 2004-07-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (de) * 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
WO2004110363A2 (en) 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006033664A1 (en) 2004-03-08 2006-03-30 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US7431927B2 (en) 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
DE102005025041A1 (de) 2005-05-30 2006-12-07 Bell Flavors & Fragrances Duft Und Aroma Gmbh Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP2103628A4 (en) 2006-12-14 2012-02-22 Forerunner Pharma Res Co Ltd MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY
WO2008114733A1 (ja) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-4抗体
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2009025759A1 (en) * 2007-08-17 2009-02-26 Progenics Pharmaceuticals (Nevada), Inc. Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
WO2009028663A1 (ja) 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
EP2060583A1 (en) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CA2711557A1 (en) 2008-01-11 2009-07-16 The University Of Tokyo Anti-cldn6 antibody
AU2009234259A1 (en) * 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of Gleditsia sinensis Lam
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
DE102009026966A1 (de) 2008-12-18 2010-07-01 Robert Bosch Gmbh Betrieb eines Bremskraftverstärkers als Pedalsimulator
JP2010178650A (ja) 2009-02-04 2010-08-19 Univ Of Tokyo 固形癌の再発予測のための試験方法および再発予防剤
EP2221063A1 (en) * 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
CN107028969A (zh) 2009-02-20 2017-08-11 加尼梅德药物公司 用于癌症诊断和治疗的方法和组合物
DE102009010019B4 (de) 2009-02-21 2012-05-31 Jos. Schneider Optische Werke Gmbh Verfahren zum berührungslosen Messen der Topographie
EP2322555A1 (en) 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
WO2011057788A1 (en) 2009-11-11 2011-05-19 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
WO2011105551A1 (ja) 2010-02-26 2011-09-01 国立大学法人大阪大学 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
JP6077997B2 (ja) 2011-09-07 2017-02-08 中外製薬株式会社 癌幹細胞の分離
EP2605017A1 (de) 2011-12-16 2013-06-19 Protagen AG Markersequenzen für gynäkologisches Malignom und deren Verwendung
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells

Also Published As

Publication number Publication date
IL214256A0 (en) 2011-09-27
US20230193261A1 (en) 2023-06-22
BRPI1008564B1 (pt) 2021-10-05
EP4285911A3 (en) 2024-04-10
EP4285911A2 (en) 2023-12-06
CA2750985A1 (en) 2010-08-26
IL258794A (en) 2018-06-28
WO2010094499A1 (en) 2010-08-26
EP2398902A1 (en) 2011-12-28
US20110300144A1 (en) 2011-12-08
IL236516B (en) 2018-05-31
KR102340685B1 (ko) 2021-12-17
KR20110128316A (ko) 2011-11-29
AU2010215700B2 (en) 2015-11-19
EP2398902B1 (en) 2023-10-04
AU2016201051A1 (en) 2016-03-10
CN102325885A (zh) 2012-01-18
AU2016201051B2 (en) 2018-02-08
US11473085B2 (en) 2022-10-18
MX345316B (es) 2017-01-23
HRP20231525T1 (hr) 2024-03-15
CA2750985C (en) 2022-07-19
KR20180098701A (ko) 2018-09-04
MX2011008430A (es) 2011-09-29
RS64937B1 (sr) 2024-01-31
IL258794B (en) 2019-06-30
SI2398902T1 (sl) 2024-04-30
KR102152997B1 (ko) 2020-09-07
SG10201402493UA (en) 2014-10-30
CN107028969A (zh) 2017-08-11
US9809815B2 (en) 2017-11-07
KR20200105549A (ko) 2020-09-07
FI2398902T3 (fi) 2023-11-28
DK2398902T3 (da) 2023-12-04
ES2963717T3 (es) 2024-04-01
PL2398902T3 (pl) 2024-02-26
ZA201105471B (en) 2012-10-31
LT2398902T (lt) 2023-12-27
SG173444A1 (en) 2011-09-29
AU2010215700A1 (en) 2011-08-18
IL236516A0 (en) 2015-02-26
BRPI1008564A2 (pt) 2018-02-27
JP5808254B2 (ja) 2015-11-10
NZ594480A (en) 2013-11-29
SG10202005849RA (en) 2020-07-29
US20190169614A1 (en) 2019-06-06
US20180119146A1 (en) 2018-05-03
JP2012518609A (ja) 2012-08-16
PT2398902T (pt) 2023-12-05
IL267342B (en) 2021-12-01
IL267342A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2011008430A (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
MX2011008429A (es) Metodos y composiciones para diagnostico y tratamiento del cancer.
EP3173092A3 (en) Rna containing composition for treatment of tumor diseases
WO2013182912A3 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
EA201590986A1 (ru) Антитела к ceacam5 и их применения
WO2012068383A3 (en) ncRNA AND USES THEREOF
EP2285989A4 (en) NEW TARGETS TO REGULATE ANGIOGENESIS
MY162741A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin D1
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
WO2012122370A3 (en) Compositions and methods useful for treating diseases
MX2015000821A (es) Compuestos para inmunoterapia dirigida.
WO2012174256A3 (en) Dna methylation profiles in cancer
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
IN2012MN02591A (es)
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
EP2373794A4 (en) NECTINE-4 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS OF CANCER
WO2008086182A3 (en) Use of gene signatures to design novel cancer treatment regimens
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
EP2329044A4 (en) PRMT1 FOR TARGET GENES FOR THE TREATMENT AND DIAGNOSIS OF CANCER
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
MX2022014326A (es) Proteinas multiespecificas.
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2009008990A3 (en) Methods and compositions for treatment of cancer and other angiogenesis - related diseases
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase